How much does Upatinib cost? Is it covered by medical insurance?

Upadacitinib is a JAK1 selective inhibitor, mainly used to treat immune-related diseases such as rheumatoid arthritis and atopic dermatitis. The drug has been officially launched in the Chinese market and has been included in the national medical insurance catalog. Patients can enjoy part of the cost reimbursement through medical insurance. After being included in medical insurance, the actual price of upadatinib has dropped, making it significantly more affordable among domestic patients.

In China, after upadatinib is included in medical insurance, the patient’s out-of-pocket price is about 2,000 yuan per month. This price is significantly lower than before it was included in medical insurance, providing greater financial support to patients who require long-term drug treatment. However, specific prices and medical insurance reimbursement ratios will vary depending on region and hospital policies, so patients need to check with their local hospital pharmacy for details in order to obtain the latest price and reimbursement information.

In contrast, upadatinib is also sold as a generic drug in foreign markets. Among them, the price of generic drugs in Laos and Bangladesh is relatively low, and the monthly cost is usually around six to seven hundred yuan. The ingredients of these generic drugs are basically the same as those of domestic original drugs, and they are an alternative option for patients to consider when the cost is high. However, when choosing overseas generic drugs, patients need to pay attention to the source and quality assurance of the drugs, as well as personal tolerance and efficacy of the drugs.

Although the price of generic drugs is lower, domestic original drugs have certain advantages in terms of quality, production standards and drug safety. Especially in the long-term treatment process, the stability and traceability of drugs are particularly important. For patients covered by medical insurance, it is more convenient and secure to choose domestic upadatinib.

In general, after upadatinib was launched in China and included in medical insurance, the cost of treatment for patients has been significantly reduced, helping more patients to obtain standardized treatment. At the same time, patients who need lower-cost drugs can also consider choosing foreign generic drugs. Before using any medication, patients are advised to fully communicate with their doctor to ensure the safety and effectiveness of the treatment.